Drugs / Recombinant human arginase 1
Recombinant human arginase 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01551628 | Apr 2012 → May 2013 | leukemia, lymphoma | Bio-Cancer Treatment International Limited | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human arginase 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01551628 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Arginase 1 (rhArg1)” NCT01551628 ↗ |
| Route | Intravenous | “Patients will receive weekly IV infusions of PEG-BCT-100” NCT01551628 ↗ |